Drug Profile

EZM 8266

Alternative Names: EZM-8266

Latest Information Update: 23 Aug 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Epizyme
Class Antianaemics; Small molecules
Mechanism of Action Histone-lysine N-methyltransferase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Liver cancer
Discontinued Sickle cell anaemia

Most Recent Events

21 Jun 2023 Preclinical trials in Liver cancer in USA (unspecified route) before June 2023
21 Jun 2023 Pharmacodynamic and safety data from a preclinical presented at the European Association for the Study of the Liver Congress 2023 (EASL-2023)
12 Aug 2022 Epizyme has been acquired by Ipsen

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com